Pasar al contenido principal

Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudio de aplicabilidad traslacional

PI22/00708

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment and Monitoring of Eosinophilic Fasciitis

  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Gil Vila, Albert|||0000-0003-2786-2009
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Matas-Garcia, Ana|||0000-0002-9184-8079
  • Milisenda, José César|||0000-0003-0151-7872
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • Pinal Fernandez, Iago|||0000-0001-6338-9218
Purpose of Review Eosinophilic fasciitis (EF) is a rare infammatory disease characterized by skin induration. Although some guidelines from scientifc societies exist, standard recommendations on monitoring and therapy are lacking. Recent Findings Current therapy for patients diagnosed with EF includes glucocorticoids plus at least one immunosuppressive drug in cases of relapse or refractory disease. Methotrexate and mycophenolate mofetil are the most recommended, although recently a myriad of case reports or small series reporting the efectivity of biological agents or JAK inhibitors for treating relapses or refractory disease have been published. Anti-IL5 may have a role in those rare refractory cases with persistent eosinophilia. Intravenous immunoglobulins and photopheresis (in those centers with experience) may act as adjuvant therapies. Monitoring the disease activity is a cornerstone to ascertain if the treatment is useful or not. MRI, PET/TC, and more specifcally POCUS have recently demonstrated their value for assessing therapy response. Summary High-quality data focused on therapy and monitoring is lacking in EF. Strategies for improving scientifc quality of observational studies and consensus about "activity", "sequela", "relapse" or "refractoriness" terms in EF patients are necessary to implement prospective clinical trials and generate evidence-based medicine. Meanwhile we have to deal with the available information.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of a psychoeducational intervention on myositis patients' quality of life and well-being, a randomized controlled trial

  • Armadans Tremolosa, Immaculada|||0000-0003-2690-0544
  • Palacin Lois, Maria Ramona|||0000-0001-7931-1466
  • Castrechini Trotta, Ángela|||0000-0003-3241-5254
  • Sanduvete-Chaves, Susana|||0000-0001-8568-6168
  • Chacón-Moscoso, Salvador|||0000-0002-6401-7384
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
Myositis is a rare disease associated with impaired health-related quality of life. A study evaluating the effectiveness of an intervention to improve the quality of life and well-being of myositis patients is presented. All myositis patients in a health district were contacted. Thirty-four eligible patients were randomly assigned to the experimental (n = 17) or control (n = 17) group. A psychoeducational intervention of 5 100-min sessions focusing on the disease as related to daily life was conducted only in experimental patients. Several reliable tools to measure quality of life and well-being were administered twice, before and after the intervention, to both groups. In the experimental group, post-test scores were higher than pre-test in quality of life, well-being, and self-efficacy to manage the disease. Improvements were more evident in the experimental group than controls in 70% of the variables studied. Specifically, sedentariness decreased and satisfaction with social relationships increased in the post-test evaluation to a greater degree in the experimental group than in controls. This randomized controlled trial on a representative sample of myositis patients in an extensive population provides evidence indicating the effectiveness of a psychoeducational intervention for improving HRQoL, well-being, and self-efficacy to manage the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment Algorithms for Inflammatory Myopathies in Adults, from Guidelines to Clinical Practice

  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Gil Vila, Albert|||0000-0003-2786-2009
  • Matas-Garcia, Ana|||0000-0002-9184-8079
  • Edo-Fernandez, Clara
  • Milisenda, José César|||0000-0003-0151-7872
  • Pinal Fernandez, Iago|||0000-0001-6338-9218
Purpose of Review Inflammatory myopathies are a heterogeneous group of systemic autoimmune disorders with highly variable clinical presentations. The limited number of clinical trials has hindered the development of strong evidence-based management strategies. Therefore, there is a pressing need for consensus-driven treatment guidelines tailored to the various clinical and immunological phenotypes. This review combines existing published guidelines with the authors' clinical experience to provide a comprehensive, pragmatic approach to management. Recent Findings A comparative review of existing treatment guidelines was recently published, revealing significant heterogeneity in therapeutic approaches and recommendations. This observation is consistent with our own experience during a multidisciplinary meeting, primarily involving internal medicine specialists and rheumatologists. Furthermore, recent clinical trials and observational studies investigating novel therapies offer promising prospects that could influence future clinical decision-making. Summary Although establishing a unified therapeutic algorithm remains challenging, this review aims to translate current knowledge into clinical practice by integrating existing guidelines, our own clinical experience, and the most recent evidence published on the topic.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Treatment and Monitoring of Eosinophilic Fasciitis

  • Gil-Vila, Albert
  • Matas Garcia, Ana
  • Milisenda, José César
  • Selva-O'Callaghan, Albert
  • Trallero-Araguás, Ernesto
  • Guillen-Del-Castillo, Alfredo
  • Simeón-Aznar , Carmen Pilar
Eosinophilic fasciitis; Groove sign; Immunosuppressive treatment, Fascitis eosinofílica; Signo del surco; Tratamiento inmunosupresor, Fasciitis eosinofílica; Signe de solc; Tractament immunosupressor, Purpose of Review Eosinophilic fasciitis (EF) is a rare inflammatory disease characterized by skin induration. Although some guidelines from scientific societies exist, standard recommendations on monitoring and therapy are lacking. Recent Findings Current therapy for patients diagnosed with EF includes glucocorticoids plus at least one immunosuppressive drug in cases of relapse or refractory disease. Methotrexate and mycophenolate mofetil are the most recommended, although recently a myriad of case reports or small series reporting the effectivity of biological agents or JAK inhibitors for treating relapses or refractory disease have been published. Anti-IL5 may have a role in those rare refractory cases with persistent eosinophilia. Intravenous immunoglobulins and photopheresis (in those centers with experience) may act as adjuvant therapies. Monitoring the disease activity is a cornerstone to ascertain if the treatment is useful or not. MRI, PET/TC, and more specifically POCUS have recently demonstrated their value for assessing therapy response. Summary High-quality data focused on therapy and monitoring is lacking in EF. Strategies for improving scientific quality of observational studies and consensus about “activity”, “sequela”, “relapse” or “refractoriness” terms in EF patients are necessary to implement prospective clinical trials and generate evidence-based medicine. Meanwhile we have to deal with the available information., Open Access Funding provided by Universitat Autonoma de Barcelona. Instituto de Salud Carlos III co-financed by the European Regional Development Fund (ERDF) PI22/00708. Grant recipient: Ernesto Trallero-Araguás and Albert Selva-O’Callaghan.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Treatment and Monitoring of Eosinophilic Fasciitis

  • Gil-Vila, Albert
  • Matas Garcia, Ana
  • Milisenda, José César
  • Selva-O'Callaghan, Albert
  • Trallero-Araguás, Ernesto
  • Guillen-Del-Castillo, Alfredo
  • Simeón-Aznar , Carmen Pilar
Eosinophilic fasciitis; Groove sign; Immunosuppressive treatment, Fascitis eosinofílica; Signo del surco; Tratamiento inmunosupresor, Fasciitis eosinofílica; Signe de solc; Tractament immunosupressor, Purpose of Review Eosinophilic fasciitis (EF) is a rare inflammatory disease characterized by skin induration. Although some guidelines from scientific societies exist, standard recommendations on monitoring and therapy are lacking. Recent Findings Current therapy for patients diagnosed with EF includes glucocorticoids plus at least one immunosuppressive drug in cases of relapse or refractory disease. Methotrexate and mycophenolate mofetil are the most recommended, although recently a myriad of case reports or small series reporting the effectivity of biological agents or JAK inhibitors for treating relapses or refractory disease have been published. Anti-IL5 may have a role in those rare refractory cases with persistent eosinophilia. Intravenous immunoglobulins and photopheresis (in those centers with experience) may act as adjuvant therapies. Monitoring the disease activity is a cornerstone to ascertain if the treatment is useful or not. MRI, PET/TC, and more specifically POCUS have recently demonstrated their value for assessing therapy response. Summary High-quality data focused on therapy and monitoring is lacking in EF. Strategies for improving scientific quality of observational studies and consensus about “activity”, “sequela”, “relapse” or “refractoriness” terms in EF patients are necessary to implement prospective clinical trials and generate evidence-based medicine. Meanwhile we have to deal with the available information., Open Access Funding provided by Universitat Autonoma de Barcelona. Instituto de Salud Carlos III co-financed by the European Regional Development Fund (ERDF) PI22/00708. Grant recipient: Ernesto Trallero-Araguás and Albert Selva-O’Callaghan.